To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of € 1.0 m to Evotec.
The milestone was for the transition of a back-up compound from a respiratory programme into pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We have now achieved twenty three milestones as part of the collaboration with Boehringer Ingelheim. The completed research phase of this alliance has led to significant potential clinical milestones and royalties for compounds that are already in pre-clinical and clinical development if they progress successfully.”
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
